G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

G1 Therapeutics

04/05/2022 14:31

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of $1.15​​ per share for the quarter ended in March. The mean
expectation of eight analysts for the quarter was for a loss
of 97 cents per share.
    * Revenue fell 51.5% to $6.90 million from a year ago; 
analysts
expected $6.69 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss of
$1.15​.
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * G1 Therapeutics Inc shares had fallen by 28.0% this
quarter and
lost 46.4% so far this year.
    * The company reported a quarterly loss of $49.19 million.
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $39.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated May 4 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated